We demonstrated a significant enrichment in MYD88, CD79B, PIM1, and KMT2D mutations in CD5+ DLBCL (Figure 2E), which implied that applying the corresponding inhibitors might improve the treatment outcome of this group. Here, KMT2D is linked to diffuse large B-cell lymphoma.